A 3.6 Ma sedimentological, geochemical and palynological record of sediment core ICDP5011-1 in Lake Elgygytgyn, NE Russia

Understanding the evolution of Arctic polar climate from the protracted warmth of the middle Pliocene into the earliest glacial cycles in the Northern Hemisphere has been hindered by the lack of continuous, highly resolved Arctic time series. Evidence from Lake El'gygytgyn, NE Arctic Russia, shows that 3.6-3.4 million years ago, summer temperatures were ~8°C warmer than today when pCO2 was ~400 ppm. Multiproxy evidence suggests extreme warmth and polar amplification during the middle Pliocene, sudden stepped cooling events during the Pliocene-Pleistocene transition, and warmer than present Arctic summers until ~2.2 Ma, after the onset of Northern Hemispheric glaciation. Our data are consistent with sea-level records and other proxies indicating that Arctic cooling was insufficient to support large-scale ice sheets until the early Pleistocene.

Hemocompatibility of poly(epsilon-caprolactone) lipid-core nanocapsules stabilized with polysorbate 80-lecithin and uncoated or coated with chitosan

The hemocompatibility of nanoparticles is of critical importance for their systemic administration as drug delivery systems. Formulations of lipid-core nanocapsules, stabilized with polysorbate 80-lecithin and uncoated or coated with chitosan (LNC and LNC-CS), were prepared and characterized by laser diffraction (D[4,3]: 129 and 134 nm), dynamic light scattering (119 nm and 133 nm), nanoparticle tracking (D50: 124 and 139 nm) and particle mobility (zeta potential: -15.1 mV and + 9.3 mV) analysis. In vitro hemocompatibility studies were carried out with mixtures of nanocapsule suspensions in human blood at 2% and 10% (v/v). The prothrombin time showed no significant change independently of the nanocapsule surface potential or its concentration in plasma. Regarding the activated partial thromboplastin time, both suspensions at 2% (v/v) in plasma did not influence the clotting time. Even though suspensions at 10% (v/v) in plasma decreased the clotting times (p < 0.05), the values were within the normal range. The ability of plasma to activate the coagulation system was maintained after the addition of the formulations. Suspensions at 2% (v/v) in blood showed no significant hemolysis or platelet aggregation. In conclusion, the lipid-core nanocapsules uncoated or coated with chitosan are hemocompatible representing a potential innovative nanotechnological formulation for intravenous administration. (C) 2012 Elsevier B. V. All rights reserved.

Influence of nucleus accumbens core or shell stimulation on early long-term potentiation in the dentate gyrus of freely moving rats

Magdeburg, Univ., Fak. für Naturwiss., Diss., 2010

Photoelastic analysis of forces generated by T-loop springs made with stainless steel or titanium-molybdenum alloy

Introduction: The purpose of this study was to use photoelastic analysis to compare the system of forces generated by retraction T-loop springs made with stainless steel and titanium-molybdenum alloy (TMA) (Ormco, Glendora, Calif) with photoelastic analysis. Methods: Three photoelastic models were used to evaluate retraction T-loop springs with the same preactivations in 2 groups. In group 1, the loop was constructed with a stainless steel wire, and 2 helicoids were incorporated on top of the T-loop; in group 2, it was made with TMA and no helicoids. Results: Upon using the qualitative analysis of the fringe order in the photoelastic model, it was observed that the magnitude of force generated by the springs in group 1 was significantly higher than that in group 2. However, both had symmetry for the active and reactive units related to the system of force. Conclusions: Both springs had the same mechanical characteristics. TMA springs showed lower force levels. (Am J Orthod Dentofacial Orthop 2011;140:e123-e128)

Accumulation of organic carbon in the Laptev Sea

Composition and accumulation rates of organic carbon in Holocene sediments provided data to calculate an organic carbon budget for the Laptev Sea continental margin. Mean Holocene accumulation rates in the inner Laptev Sea vary between 0.14 and 2.7 g C cm**2/ky; maximum values occur close to the Lena River delta. Seawards, the mean accumulation rates decrease from 0.43 to 0.02 g C cm**2/ky. The organic matter is predominantly of terrigenous origin. About 0.9*10**6 t/year of organic carbon are buried in the Laptev Sea, and 0.25*10**6 t/year on the continental slope. Between about 8.5 and 9 ka, major changes in supply of terrigenous and marine organic carbon occur, related to changes in coastal erosion, Siberian river discharge, and/or Atlantic water inflow along the Eurasian continental margin.

Bortezomib(Velcade (R))-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation.

Introduction: The Thalidomide-Dexamethasone (TD) regimen has provided encouraging results in relapsed MM. To improve results, bortezomib (Velcade) has been added to the combination in previous phase II studies, the so called VTD regimen. In January 2006, the European Group for Blood and Marrow Transplantation (EBMT) and the Intergroupe Francophone du Myélome (IFM) initiated a prospective, randomized, parallel-group, open-label phase III, multicenter study, comparing VTD (arm A) with TD (arm B) for MM patients progressing or relapsing after autologous transplantation. Patients and Methods: Inclusion criteria: patients in first progression or relapse after at least one autologous transplantation, including those who had received bortezomib or thalidomide before transplant. Exclusion criteria: subjects with neuropathy above grade 1 or non secretory MM. Primary study end point was time to progression (TTP). Secondary end points included safety, response rate, progression-free survival (PFS) and overall survival (OS). Treatment was scheduled as follows: bortezomib 1.3 mg/m2 was given as an i.v bolus on Days 1, 4, 8 and 11 followed by a 10-Day rest period (days 12 to 21) for 8 cycles (6 months) and then on Days 1, 8, 15, 22 followed by a 20-Day rest period (days 23 to 42) for 4 cycles (6 months). In both arms, thalidomide was scheduled at 200 mg/Day orally for one year and dexamethasone 40 mg/Day orally four days every three weeks for one year. Patients reaching remission could proceed to a new stem cell harvest. However, transplantation, either autologous or allogeneic, could only be performed in patients who completed the planned one year treatment period. Response was assessed by EBMT criteria, with additional category of near complete remission (nCR). Adverse events were graded by the NCI-CTCAE, Version 3.0.The trial was based on a group sequential design, with 4 planned interim analyses and one final analysis that allowed stopping for efficacy as well as futility. The overall alpha and power were set equal to 0.025 and 0.90 respectively. The test for decision making was based on the comparison in terms of the ratio of the cause-specific hazards of relapse/progression, estimated in a Cox model stratified on the number of previous autologous transplantations. Relapse/progression cumulative incidence was estimated using the proper nonparametric estimator, the comparison was done by the Gray test. PFS and OS probabilities were estimated by the Kaplan-Meier curves, the comparison was performed by the Log-Rank test. An interim safety analysis was performed when the first hundred patients had been included. The safety committee recommended to continue the trial. Results: As of 1st July 2010, 269 patients had been enrolled in the study, 139 in France (IFM 2005-04 study), 21 in Italy, 38 in Germany, 19 in Switzerland (a SAKK study), 23 in Belgium, 8 in Austria, 8 in the Czech republic, 11 in Hungary, 1 in the UK and 1 in Israel. One hundred and sixty nine patients were males and 100 females; the median age was 61 yrs (range 29-76). One hundred and thirty six patients were randomized to receive VTD and 133 to receive TD. The current analysis is based on 246 patients (124 in arm A, 122 in arm B) included in the second interim analysis, carried out when 134 events were observed. Following this analysis, the trial was stopped because of significant superiority of VTD over TD. The remaining patients were too premature to contribute to the analysis. The number of previous autologous transplants was one in 63 vs 60 and two or more in 61 vs 62 patients in arm A vs B respectively. The median follow-up was 25 months. The median TTP was 20 months vs 15 months respectively in arm A and B, with cumulative incidence of relapse/progression at 2 years equal to 52% (95% CI: 42%-64%) vs 70% (95% CI: 61%-81%) (p=0.0004, Gray test). The same superiority of arm A was also observed when stratifying on the number of previous autologous transplantations. At 2 years, PFS was 39% (95% CI: 30%-51%) vs 23% (95% CI: 16%-34%) (A vs B, p=0.0006, Log-Rank test). OS in the first two years was comparable in the two groups. Conclusion: VTD resulted in significantly longer TTP and PFS in patients relapsing after ASCT. Analysis of response and safety data are on going and results will be presented at the meeting. Protocol EU-DRACT number: 2005-001628-35.

Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation

Introduction: The Thalidomide-Dexamethasone (TD) regimen has provided encouraging results in relapsed MM. To improve results, bortezomib (Velcade) has been added to the combination in previous phase II studies, the so called VTD regimen. In January 2006, the European Group for Blood and Marrow Transplantation (EBMT) and the Intergroupe Francophone du Myélome (IFM) initiated a prospective, randomized, parallel-group, open-label phase III, multicenter study, comparing VTD (arm A) with TD (arm B) for MM patients progressing or relapsing after autologous transplantation. Patients and Methods: Inclusion criteria: patients in first progression or relapse after at least one autologous transplantation, including those who had received bortezomib or thalidomide before transplant. Exclusion criteria: subjects with neuropathy above grade 1 or non secretory MM. Primary study end point was time to progression (TTP). Secondary end points included safety, response rate, progression-free survival (PFS) and overall survival (OS). Treatment was scheduled as follows: bortezomib 1.3 mg/m2 was given as an i.v bolus on Days 1, 4, 8 and 11 followed by a 10-Day rest period (days 12 to 21) for 8 cycles (6 months) and then on Days 1, 8, 15, 22 followed by a 20-Day rest period (days 23 to 42) for 4 cycles (6 months). In both arms, thalidomide was scheduled at 200 mg/Day orally for one year and dexamethasone 40 mg/Day orally four days every three weeks for one year. Patients reaching remission could proceed to a new stem cell harvest. However, transplantation, either autologous or allogeneic, could only be performed in patients who completed the planned one year treatment period. Response was assessed by EBMT criteria, with additional category of near complete remission (nCR). Adverse events were graded by the NCI-CTCAE, Version 3.0.The trial was based on a group sequential design, with 4 planned interim analyses and one final analysis that allowed stopping for efficacy as well as futility. The overall alpha and power were set equal to 0.025 and 0.90 respectively. The test for decision making was based on the comparison in terms of the ratio of the cause-specific hazards of relapse/progression, estimated in a Cox model stratified on the number of previous autologous transplantations. Relapse/progression cumulative incidence was estimated using the proper nonparametric estimator, the comparison was done by the Gray test. PFS and OS probabilities were estimated by the Kaplan-Meier curves, the comparison was performed by the Log-Rank test. An interim safety analysis was performed when the first hundred patients had been included. The safety committee recommended to continue the trial. Results: As of 1st July 2010, 269 patients had been enrolled in the study, 139 in France (IFM 2005-04 study), 21 in Italy, 38 in Germany, 19 in Switzerland (a SAKK study), 23 in Belgium, 8 in Austria, 8 in the Czech republic, 11 in Hungary, 1 in the UK and 1 in Israel. One hundred and sixty nine patients were males and 100 females; the median age was 61 yrs (range 29-76). One hundred and thirty six patients were randomized to receive VTD and 133 to receive TD. The current analysis is based on 246 patients (124 in arm A, 122 in arm B) included in the second interim analysis, carried out when 134 events were observed. Following this analysis, the trial was stopped because of significant superiority of VTD over TD. The remaining patients were too premature to contribute to the analysis. The number of previous autologous transplants was one in 63 vs 60 and two or more in 61 vs 62 patients in arm A vs B respectively. The median follow-up was 25 months. The median TTP was 20 months vs 15 months respectively in arm A and B, with cumulative incidence of relapse/progression at 2 years equal to 52% (95% CI: 42%-64%) vs 70% (95% CI: 61%-81%) (p=0.0004, Gray test). The same superiority of arm A was also observed when stratifying on the number of previous autologous transplantations. At 2 years, PFS was 39% (95% CI: 30%-51%) vs 23% (95% CI: 16%-34%) (A vs B, p=0.0006, Log-Rank test). OS in the first two years was comparable in the two groups. Conclusion: VTD resulted in significantly longer TTP and PFS in patients relapsing after ASCT. Analysis of response and safety data are on going and results will be presented at the meeting.

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

PURPOSE This prospective multicenter phase III study compared the efficacy and safety of a triple combination (bortezomib-thalidomide-dexamethasone [VTD]) versus a dual combination (thalidomide-dexamethasone [TD]) in patients with multiple myeloma (MM) progressing or relapsing after autologous stem-cell transplantation (ASCT). PATIENTS AND METHODS Overall, 269 patients were randomly assigned to receive bortezomib (1.3 mg/m(2) intravenous bolus) or no bortezomib for 1 year, in combination with thalidomide (200 mg per day orally) and dexamethasone (40 mg orally once a day on 4 days once every 3 weeks). Bortezomib was administered on days 1, 4, 8, and 11 with a 10-day rest period (day 12 to day 21) for eight cycles (6 months), and then on days 1, 8, 15, and 22 with a 20-day rest period (day 23 to day 42) for four cycles (6 months). Results Median time to progression (primary end point) was significantly longer with VTD than TD (19.5 v 13.8 months; hazard ratio, 0.59; 95% CI, 0.44 to 0.80; P = .001), the complete response plus near-complete response rate was higher (45% v 25%; P = .001), and the median duration of response was longer (17.2 v 13.4 months; P = .03). The 24-month survival rate was in favor of VTD (71% v 65%; P = .093). Grade 3 peripheral neuropathy was more frequent with VTD (29% v 12%; P = .001) as were the rates of grades 3 and 4 infection and thrombocytopenia. CONCLUSION VTD was more effective than TD in the treatment of patients with MM with progressive or relapsing disease post-ASCT but was associated with a higher incidence of grade 3 neurotoxicity.

High sensitivity fiber optic angular displacement sensor and its application for detection of ultrasound

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Description and chemical composition of ferromanganese nodules from Station 123, Oneida Lake, New York

226Ra is used to document the growth histories of six manganese nodules from Oneida Lake, New York. Detailed sectioning and analysis reveal that there are discontinuous gradients in 226Ra content in these samples. These gradients result from periods of rapid growth (>1 mm/100 years) separated by periods of no growth of erosion. Although the 226Ra 'age' of the nodules approximates the age of Oneida Lake, the nodules are not sediment-covered because they occur only in areas of the lake where fine-grained sediments are not accumulating.

Investigation of sediment core PS2556 from Bellingshausen Sea, Antarctica

Die Rekonstruktion der glaziomarinen Sedimentationsprozesse am antarktischen Kontinentalrand des westlichen Bellingshausenmeeres erfolgte durch die sedimentologische Auswertung eines 962 cm langen Schwerelotkernes aus 3594 m Wassertiefe. Der Kern wurde während des Fahrtabschnittes ANT-XI/3 mit dem FS "Polarstern" vom Scheitel einer Sediment- "Drift" gezogen. An dem Sedimentkern wurde eine lithologische Beschreibung, sowie sedimentologische Untersuchungen und sedimentphysikalische Messungen durchgeführt. Anhand der Ergebnisse konnten signifikante Änderungen in der Zusammensetzung und Struktur der Sedimente erkannt, und drei Faziestypen unterschieden werden. Die Faziestypen charakterisieren jeweils glaziale oder interglaziale Zeiträume. Der größte Teil der Sedimentabfolge gehört der Laminitfazies an. Dabei handelt es sich um feinlaminierte Sedimentabschnitte, die vorwiegend aus feinkörnigen, terrigenen Komponenten zusammengesetzt sind. In die feinlaminierten Abschnitte sind vereinzelte, wenige Milimeter bis Zentimeter mächtige Siltlagen eingeschaltet. Die biogenen Anteile sind gering, Anzeichen für Bodenleben fehlen völlig. Die Manganfazies wird von authigen gebildeten Mangankonkretionen dominiert, die jeweils diskrete Lagen bilden. Dabei handelt es sich zum einen um Mikromanganknollen und -krusten und zum andern um manganhaltige Gangfüllungen. Biogene und terrigene Anteile sind in diesem Faziestyp unbedeutend. Die Biogenfazies ist von strukturlosen und stark bioturbierten Sedimenten gekennzeichnet. In diesen Sedimentabschnitten ist der hohe Anteil an Eisfracht (IRD) und die erhöhten Gehalte an Kalziumkarbonat und Opal in der Sandfraktion markant. Die stratigraphische Einordnung des Sedimentkernes erfolgte über die von Grobe & Mackensen (1992) entwickelte Lithostratigraphie, mit deren Einheiten die Faziestypen des Sedimentkernes korreliert werden konnten. Dabei ergaben sich zwei mögliche Altersmodelle und ein Basisalter von ca. 250.000 Jahren. Anhand der stratigraphischen Fixpunkte wurden Sedimentationsraten des Gesamtsedimentes und Akkumulationsraten des Kalziumkarbonates, des Biogenopals und des organisch gebundenen Kohlenstoffes berechnet. Dabei wurde gezeigt, daß lediglich das Kalziumkarbonat und der Biogenopal als Anzeiger für biologische Produktion dienen können, wobei Lösungsprozesse in der Wassersäule und im Sediment eine große Rolle spielen. Der Gehalt an organisch gebundenem Kohlenstoff ist in dem Sedimentkern nur erhaltungsbedingt zu erklären. Die Sedimentationsprozesse der einzelnen Faziestypen sind von den Eisverhältnissen, der biologischen Produktion, dem gravitativen Transport und der Umlagerung durch Meeresströmungen abhängig. Die Auswirkung der einzelnen Faktoren ist jeweils unterschiedlich ausgeprägt und wirkt sich spezifisch auf die einzelnen Parameter aus. In den Glazialen hatte ein Vorstoß des Schelfeises über die Schelfkante zur Anlieferung großer Sedimentmassen geführt, die über gravitativen Transport den Kontinentalhang hinunter transportiert wurden. Die Feinfracht wurde über parallel zum Kontinentalhang laufende Konturströme westwärts transportiert und in der Larninitfazies der Driftkörper abgelagert. Am Ende der Glaziale kam es zur Sedimentation der Manganfazies. Die geringen Sedimentationsraten am Kamm der Sedimentdrift kamen aufgrund reduzierter Intensität der Konturströme und fehlender Umlagerung von Schelfsedimenten in Folge rückschreitender Schelfeisrnassen zustande. In den Interglazialen kam es durch den aufsteigenden Meeresspiegel zum Aufschwimmen des Schelfeises. Der damit verbundene Abbau der Eisrnassen über dem Schelf, hatte eine hohe Sedimentation von IRD zur Folge. Mit fortschreitendem Interglazial kam es in Zeiten nur saisonaler Meereisbedeckung zu verstärkter biologischer Produktion und zur Sedimentation biogenen Materials.